Grown Rogue International (GRUSF) Non-Current Assets (2011 - 2026)
Grown Rogue International's (GRUSF) quarterly Non-Current Assets came in at $41.0 million in Q1 2026, up 90.58% year-on-year from $21.5 million in Q1 2025, and up 2334.24% quarter-over-quarter from $1.7 million in Q4 2025.
Grown Rogue International (GRUSF) Non-Current Assets (2011 - 2026) Analysis & Trends
Grown Rogue International's Non-Current Assets history runs 16 years deep, the most recent figure standing at $41.0 million for Q1 2026.
- On a quarterly basis, Non-Current Assets rose 90.58% year-over-year to $41.0 million in Q1 2026; TTM through Mar 2026 was $72165.3 billion, a 100827772.62% increase from a year earlier, with the FY2025 full-year figure at $1.7 million, up 9.48% from the prior year.
- Non-Current Assets grew to $41.0 million in Q1 2026 per GRUSF's latest filing, from $1.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $48078.5 billion in Q2 2025 and bottomed at $1.5 million in Q4 2024.
- The 5-year median for Non-Current Assets is $13.9 million (2023), against an average of $5154.7 billion.
- Across the five-year window, Non-Current Assets tumbled 85.05% in 2024 and soared 320009577.44% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $8.5 million in 2022, then advanced by 21.58% to $10.3 million in 2023, then tumbled by 85.05% to $1.5 million in 2024, then climbed by 9.48% to $1.7 million in 2025, then surged by 2334.24% to $41.0 million in 2026.
- Per Business Quant, the three latest GRUSF Non-Current Assets figures stand at $41.0 million (Q1 2026), $1.7 million (Q4 2025), and $24086.7 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 40.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.99 Mn |
| Dec 31, 2025 | 1.68 Mn |
| Sep 30, 2025 | 24,086.70 Bn |
| Jun 30, 2025 | 48,078.50 Bn |
| Mar 31, 2025 | 21.51 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 16.38 Mn |
| Jun 30, 2024 | 15.02 Mn |
| Mar 31, 2024 | 18.66 Mn |
| Dec 31, 2023 | 10.29 Mn |
| Oct 31, 2023 | 12.74 Mn |
| Apr 30, 2023 | 8.54 Mn |
| Jan 31, 2023 | 8.61 Mn |
| Oct 31, 2022 | 8.46 Mn |
| Oct 31, 2021 | 14.21 Mn |
| Apr 30, 2021 | 5.05 Mn |
| Jan 31, 2021 | 3.00 Mn |
| Oct 31, 2020 | 3.69 Mn |
| Jul 31, 2020 | 2.13 Mn |
| Apr 30, 2020 | 2.19 Mn |